Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)

NCT01931046 is registered in ClinicalTrials.gov with Momotaro-Gene Inc. as lead sponsor.

NCT NCT01931046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01931046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)
Lead sponsor
Momotaro-Gene Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2013
Completion date
March 31, 2020
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate cancer